Skip to content
Clinical Trials – home
CroatiaBack to Croatia

Clinical trials in Cepin – page 6

88 clinical trials in Cepin, Croatia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CroatiaOur site in CroatiaKlinicka-Ispitivanja.hr(opens in a new tab)
Cepin at a glance
88
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

88 trials in Cepin

Open in trial search

Study of oral and injectable NNC0487-0111 (Amycretin) to find the best dose for blood sugar control in adults with type 2 diabetes taking metformin with or without SGLT2 inhibitor

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Metformin Embonate
  • Sponsor:Novo Nordisk A/S

Colitis ulcerative

Not recruiting

Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:EYE103
  • Sponsor:Eyebiotech Limited

Systemic scleroderma

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod PH20 SC for Adults with Systemic Sclerosis

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Crohn's disease

Not recruiting

Study of SAR441566 compared to placebo for adults with moderate to severe Crohn's disease

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Balinatunfib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immutep

Comparison of two doses of cabozantinib (60 mg vs 140 mg) in patients with progressive metastatic medullary thyroid cancer

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Exelixis Inc.

Study Comparing ABP 206 and Nivolumab for Patients with Unresectable or Metastatic Melanoma

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Amgen Inc.

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Study Comparing Epcoritamab and Lenalidomide with a Drug Combination for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of Sparsentan and Dapagliflozin for Patients with Immunoglobulin A Nephropathy (IgAN)

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Travere Therapeutics Inc.

Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Other cities in Croatia

The busiest research cities in the country

All 26 cities in Croatia

Clinical research in Cepin

What the registry says about research in the country

01 Cardiovascular Diseases

Clinical trial activity in Cepin is focused entirely on cardiovascular diseases, with studies exploring new ways to reduce heart-related events and improve long-term outcomes for people living with complex heart conditions.

  • Chronic heart failure
  • Heart failure with mildly reduced or preserved ejection fraction
  • Heart failure with reduced ejection fraction
  • Heart condition

These trials are mainly testing whether newer treatments can better control inflammation, protect the heart, and lower the risk of hospitalization or cardiovascular death.

02 Heart Failure and Inflammation

Several studies are examining heart failure together with systemic inflammation, aiming to see whether targeted therapy can improve outcomes for patients with HFmrEF and HFpEF.

  • HFmrEF
  • HFpEF
  • Systemic inflammation
  • Cardiovascular death and heart failure events

This research is designed to evaluate a potential new treatment approach for people whose heart failure is linked with inflammatory activity.

03 Heart Failure Treatment Options

Another important area of research is the management of heart failure in patients who cannot use standard mineralocorticoid receptor antagonists, with studies looking at both effectiveness and safety.

  • HFrEF
  • Finerenone
  • Safety and tolerability
  • Standard heart failure care

These trials are intended to expand treatment options for people with limited access to current therapies.

04 Diabetes, Hypertension, and Cardiovascular Risk

Research in the city also includes patients with type 2 diabetes, hypertension, and established cardiovascular disease, reflecting the close link between metabolic and heart health.

  • Type 2 diabetes
  • High blood pressure
  • Established cardiovascular disease
  • Heart-related hospital visits

These studies are focused on whether combining therapies can better prevent serious cardiovascular events in high-risk patients.

05 Iron Deficiency in Chronic Heart Failure

One trial is exploring whether treating iron deficiency in people with symptomatic chronic heart failure can improve survival and reduce worsening heart failure.

  • Symptomatic chronic heart failure
  • Iron deficiency
  • Ferric derisomaltose
  • Hospitalization prevention

This line of research aims to clarify the role of iron replacement as part of comprehensive heart failure care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.